Schedule of ratings—skin

The Skin

Description Percentage

With visible or palpable tissue loss and either gross distortion or asymmetry of three or more features or paired sets of features (nose, chin, forehead, eyes (including eyelids), ears (auricles), cheeks, lips), or; with six or more characteristics of disfigurement

80
Description Percentage

With visible or palpable tissue loss and either gross distortion or asymmetry of two features or paired sets of features (nose, chin, forehead, eyes (including eyelids), ears (auricles), cheeks, lips), or; with four or five characteristics of disfigurement

50
Description Percentage

With visible or palpable tissue loss and either gross distortion or asymmetry of one feature or paired set of features (nose, chin, forehead, eyes (including eyelids), ears (auricles), cheeks, lips), or; with two or three characteristics of disfigurement

30
Description Percentage

With one characteristic of disfigurement

10

Note (1): The 8 characteristics of disfigurement, for purposes of evaluation under §4.118, are:

Scar 5 or more inches (13 or more cm.) in length. Scar at least one-quarter inch (0.6 cm.) wide at widest part.

Surface contour of scar elevated or depressed on palpation.

Scar adherent to underlying tissue.

Skin hypo-or hyper-pigmented in an area exceeding six square inches (39 sq. cm.).

Skin texture abnormal (irregular, atrophic, shiny, scaly, etc.) in

an area exceeding six square inches (39 sq. cm.).

Underlying soft tissue missing in an area exceeding six square inches (39 sq. cm.).

Skin indurated and inflexible in an area exceeding six square inches (39 sq. cm.).

 

Note (2): Rate tissue loss of the auricle under DC 6207 (loss of auricle) and anatomical loss of the eye under DC 6061 (anatomical loss of both eyes) or DC 6063 (anatomical loss of one eye), as appropriate.

Note (3): Take into consideration unretouched color photographs when evaluating under these criteria.

Note (4): Separately evaluate disabling effects other than disfigurement that are associated with individual scar(s) of the head, face, or neck, such as pain, instability, and residuals of associated muscle or nerve injury, under the appropriate diagnostic code(s) and apply § 4.25 to combine the evaluation(s) with the evaluation assigned under this diagnostic code.

Note (5): The characteristic(s) of disfigurement may be caused by one scar or by multiple scars; the characteristic(s) required to assign a particular evaluation need not be caused by a single scar in order to assign that evaluation.

Description Percentage

With visible or palpable tissue loss and either gross distortion or asymmetry of three or more features or paired sets of features (nose, chin, forehead, eyes (including eyelids), ears (auricles), cheeks, lips), or; with six or more characteristics of disfigurement

80

Description Percentage

Area or areas of 144 square inches (929 sq. cm.) or greater

40
Description Percentage

Area or areas of at least 72 square inches (465 sq. cm.) but less than 144 square inches (929 sq. cm.)

30
Description Percentage

Area or areas of at least 12 square inches (77 sq. cm.) but less than 72 square inches (465 sq. cm.)

20
Description Percentage

Area or areas of at least 6 square inches (39 sq. cm.) but less than 12 square inches (77 sq. cm.)

10

Description Percentage

Five or more scars that are unstable or painful

30
Description Percentage

Three or four scars that are unstable or painful

20
Description Percentage

One or two scars that are unstable or painful

10

Note (1): An unstable scar is one where, for any reason, there is frequent loss of covering of skin over the scar.

 

Note (2): If one or more scars are both unstable and painful, add 10 percent to the evaluation that is based on the total number of unstable or painful scars.

 

Note (3): Scars evaluated under diagnostic codes 7800, 7801, , or 7805 may also receive an evaluation under this diagnostic code, when applicable.

Evaluate any disabling effect(s) not considered in a rating provided under diagnostic codes 7800-04 under an appropriate diagnostic code

Description Percentage

With visible or palpable tissue loss and either gross distortion or asymmetry of three or more features or paired sets of features (nose, chin, forehead, eyes (including eyelids), ears (auricles), cheeks, lips), or; with six or more characteristics of disfigurement

80
Description Percentage

With visible or palpable tissue loss and either gross distortion or asymmetry of two features or paired sets of features (nose, chin, forehead, eyes (including eyelids), ears (auricles), cheeks, lips), or; with four or five characteristics of disfigurement

50
Description Percentage

With visible or palpable tissue loss and either gross distortion or asymmetry of one feature or paired set of features (nose, chin, forehead, eyes (including eyelids), ears (auricles), cheeks, lips), or; with two or three characteristics of disfigurement

30
Description Percentage

With one characteristic of disfigurement

10

Note (1): The 8 characteristics of disfigurement, for purposes of evaluation under §4.118, are:

Scar 5 or more inches (13 or more cm.) in length. Scar at least one-quarter inch (0.6 cm.) wide at widest part.

Surface contour of scar elevated or depressed on palpation.

Scar adherent to underlying tissue.

Skin hypo-or hyper-pigmented in an area exceeding six square inches (39 sq. cm.).

Skin texture abnormal (irregular, atrophic, shiny, scaly, etc.) in

an area exceeding six square inches (39 sq. cm.).

Underlying soft tissue missing in an area exceeding six square inches (39 sq. cm.).

Skin indurated and inflexible in an area exceeding six square inches (39 sq. cm.).

 

Note (2): Rate tissue loss of the auricle under DC 6207 (loss of auricle) and anatomical loss of the eye under DC 6061 (anatomical loss of both eyes) or DC 6063 (anatomical loss of one eye), as appropriate.

Note (3): Take into consideration unretouched color photographs when evaluating under these criteria.

Note (4): Separately evaluate disabling effects other than disfigurement that are associated with individual scar(s) of the head, face, or neck, such as pain, instability, and residuals of associated muscle or nerve injury, under the appropriate diagnostic code(s) and apply § 4.25 to combine the evaluation(s) with the evaluation assigned under this diagnostic code.

Note (5): The characteristic(s) of disfigurement may be caused by one scar or by multiple scars; the characteristic(s) required to assign a particular evaluation need not be caused by a single scar in order to assign that evaluation.

Description Percentage

With visible or palpable tissue loss and either gross distortion or asymmetry of three or more features or paired sets of features (nose, chin, forehead, eyes (including eyelids), ears (auricles), cheeks, lips), or; with six or more characteristics of disfigurement

80
Description Percentage

Area or areas of 144 square inches (929 sq. cm.) or greater

40
Description Percentage

Area or areas of at least 72 square inches (465 sq. cm.) but less than 144 square inches (929 sq. cm.)

30
Description Percentage

Area or areas of at least 12 square inches (77 sq. cm.) but less than 72 square inches (465 sq. cm.)

20
Description Percentage

Area or areas of at least 6 square inches (39 sq. cm.) but less than 12 square inches (77 sq. cm.)

10
Description Percentage

Five or more scars that are unstable or painful

30
Description Percentage

Three or four scars that are unstable or painful

20
Description Percentage

One or two scars that are unstable or painful

10

Note (1): An unstable scar is one where, for any reason, there is frequent loss of covering of skin over the scar.

 

Note (2): If one or more scars are both unstable and painful, add 10 percent to the evaluation that is based on the total number of unstable or painful scars.

 

Note (3): Scars evaluated under diagnostic codes 7800, 7801, , or 7805 may also receive an evaluation under this diagnostic code, when applicable.

Description Percentage

At least one of the following

60
Description Percentage

Characteristic lesions involving more than 40 percent of the entire body or more than 40 percent of exposed areas affected; or Constant or near-constant systemic therapy including, but not limited to,  corticosteroids, phototherapy, retinoids, biologics, photochemotherapy, psoralen with long-wave ultraviolet-A light (PUVA), or other immunosuppressive drugs required over the past 12-month period

60
Description Percentage

At least one of the following

30
Description Percentage

Characteristic lesions involving 20 to 40 percent of the entire body or 20 to 40 percent of exposed areas affected; or Systemic therapy including,  but not limited to, corticosteroids, phototherapy, retinoids, biologics, photochemotherapy, PUVA, or other immunosuppressive drugs required for a total duration of 6 weeks or more, but not constantly, over the past 12-month period At least one of the following

10
Description Percentage

Characteristic lesions involving at least 5 percent, but less than 20 percent, of the entire body affected; orAt least 5 percent, but less than 20 percent, of exposed areas affected; or Intermittent systemic therapy including, but not limited to, corticosteroids, phototherapy, retinoids, biologics, photochemotherapy, PUVA, or other immunosuppressive drugs required for a total duration of less than 6 weeks over the past 12-month period No more than topical therapy required over the past 12

0

Evaluate under the General Rating Formula for the Skin

Rate as disfigurement of the head, face, or neck (DC 7800), scars (DC’s 7801, , , 7804, or 7805), or dermatitis (DC 7806), depending upon the predominant disability.

Note: Evaluate non-cutaneous (visceral) leishmaniasis under DC 6301 (visceral leishmaniasis).

Rate as disfigurement of the head, face, or neck (DC 7800), scars (DC’s 7801, , , 7804, or 7805), or dermatitis (DC 7806), depending upon the predominant disability.

Note: Evaluate non-cutaneous (visceral) leishmaniasis under DC 6301 (visceral leishmaniasis).

Evaluate under the General Rating Formula for the Skin

Note: Do not combine with ratings under DC 6350

Rate under §§4.88c or 4.89, whichever is appropriate.

Evaluate under the General Rating Formula for the Skin

Evaluate under the General Rating Formula for the Skin...

Note: Rate complications and residuals of mucosal involvement (ocular, oral, gastrointestinal, respiratory, or genitourinary) separately under the appropriate diagnostic code

Evaluate under the General Rating Formula for the Skin...

Note: Rate complications such as psoriatic arthritis and other clinical manifestations (e.g., oral mucosa, nails) separately under the appropriate diagnostic code

Description Percentage

Generalized involvement of the skin with systemic manifestations (such as fever, weight loss, or hypoproteinemia) AND one of the following

100
Description Percentage

Constant or near-constant systemic therapy such as therapeutic doses of corticosteroids, other immunosuppressive drugs, retinoids, PUVA (psoralen with long-wave ultraviolet-A light), UVB (ultraviolet-B light) treatments, biologics, or electron beam therapy required over the past 12 month period; or No current treatment due to a documented history of treatment failure with 2 or more treatment regimens

100
Description Percentage

Generalized involvement of the skin without systemic manifestations and one of the following

60
Description Percentage

Constant or near-constant systemic therapy such as therapeutic doses of  corticosteroids, other immunosuppressive drugs, retinoids, PUVA, UVB treatments, biologics, or electron beam therapy required over the past 12-month period; or No current treatment due to a documented history of treatment failure with 1 or more treatment regimens

60
Description Percentage

Any extent of involvement of the skin, and any of the following therapies required for a total duration of 6 weeks or more, but not constantly, over  the past 12- month period: systemic therapy such as therapeutic doses of corticosteroids, other immunosuppressive drugs, retinoids PUVA, UVB treatments, biologics, or electron beam therapy

30
Description Percentage

Any extent of involvement of the skin, and any of the following therapies required for a total duration of less than 6 weeks over the past 12-month period: systemic therapy such as therapeutic doses of corticosteroids, other immunosuppressive drugs, retinoids, PUVA, UVB treatments, biologics, or electron beam therapy

10
Description Percentage

Any extent of involvement of the skin, and; no more than topical therapy required during the past 12-month period

0

Note: Treatment failure is defined as either disease progression, or less than a 25 percent reduction in the extent and severity of disease after four weeks of prescribed therapy, as documented by medical records....

Rate as disfigurement of the head, face, or neck (DC 7800), scars (DC’s 7801, , , 7804, or7805), or impairment of function

Note: If a skin malignancy requires therapy that is comparable to that used for systemic malignancies, i.e., systemic chemotherapy, X-ray therapy more extensive than to the skin, or surgery more extensive than wide local excision, a 100-percent evaluation will be assigned from the date of onset of treatment, and will continue, with a mandatory VA examination six months following the completion of such antineoplastic treatment, and any change in evaluation based upon that or any subsequent examination will be subject to the provisions of §3.105(e) of this chapter. If there has been no local recurrence or metastasis, evaluation will then be made on residuals. If treatment is  confined to the skin, the provisions for a 100-percent evaluation do not apply.

Rate as disfigurement of the head, face, or neck (DC 7800), scars (DC’s 7801, , , 7804, or 7805), or impairment of function

Evaluate under the General Rating Formula for the Skin

Description Percentage

With visible or palpable tissue loss and either gross distortion or asymmetry of three or more features or paired sets of features (nose, chin, forehead, eyes (including eyelids), ears (auricles), cheeks, lips), or; with six or more characteristics of disfigurement

80
Description Percentage

With visible or palpable tissue loss and either gross distortion or asymmetry of two features or paired sets of features (nose, chin, forehead, eyes (including eyelids), ears (auricles), cheeks, lips), or; with four or five characteristics of disfigurement

50
Description Percentage

With visible or palpable tissue loss and either gross distortion or asymmetry of one feature or paired set of features (nose, chin, forehead, eyes (including eyelids), ears (auricles), cheeks, lips), or; with two or three characteristics of disfigurement

30
Description Percentage

With one characteristic of disfigurement

10

Note (1): The 8 characteristics of disfigurement, for purposes of evaluation under §4.118, are:

Scar 5 or more inches (13 or more cm.) in length. Scar at least one-quarter inch (0.6 cm.) wide at widest part.

Surface contour of scar elevated or depressed on palpation.

Scar adherent to underlying tissue.

Skin hypo-or hyper-pigmented in an area exceeding six square inches (39 sq. cm.).

Skin texture abnormal (irregular, atrophic, shiny, scaly, etc.) in

an area exceeding six square inches (39 sq. cm.).

Underlying soft tissue missing in an area exceeding six square inches (39 sq. cm.).

Skin indurated and inflexible in an area exceeding six square inches (39 sq. cm.).

 

Note (2): Rate tissue loss of the auricle under DC 6207 (loss of auricle) and anatomical loss of the eye under DC 6061 (anatomical loss of both eyes) or DC 6063 (anatomical loss of one eye), as appropriate.

Note (3): Take into consideration unretouched color photographs when evaluating under these criteria.

Note (4): Separately evaluate disabling effects other than disfigurement that are associated with individual scar(s) of the head, face, or neck, such as pain, instability, and residuals of associated muscle or nerve injury, under the appropriate diagnostic code(s) and apply § 4.25 to combine the evaluation(s) with the evaluation assigned under this diagnostic code.

Note (5): The characteristic(s) of disfigurement may be caused by one scar or by multiple scars; the characteristic(s) required to assign a particular evaluation need not be caused by a single scar in order to assign that evaluation.

Description Percentage

With visible or palpable tissue loss and either gross distortion or asymmetry of three or more features or paired sets of features (nose, chin, forehead, eyes (including eyelids), ears (auricles), cheeks, lips), or; with six or more characteristics of disfigurement

80
Description Percentage

Area or areas of 144 square inches (929 sq. cm.) or greater

40
Description Percentage

Area or areas of at least 72 square inches (465 sq. cm.) but less than 144 square inches (929 sq. cm.)

30
Description Percentage

Area or areas of at least 12 square inches (77 sq. cm.) but less than 72 square inches (465 sq. cm.)

20
Description Percentage

Area or areas of at least 6 square inches (39 sq. cm.) but less than 12 square inches (77 sq. cm.)

10
Description Percentage

Five or more scars that are unstable or painful

30
Description Percentage

Three or four scars that are unstable or painful

20
Description Percentage

One or two scars that are unstable or painful

10

Evaluate any disabling effect(s) not considered in a rating provided under diagnostic codes 7800-04 under an appropriate diagnostic code

Description Percentage

With visible or palpable tissue loss and either gross distortion or asymmetry of three or more features or paired sets of features (nose, chin, forehead, eyes (including eyelids), ears (auricles), cheeks, lips), or; with six or more characteristics of disfigurement

80
Description Percentage

With visible or palpable tissue loss and either gross distortion or asymmetry of two features or paired sets of features (nose, chin, forehead, eyes (including eyelids), ears (auricles), cheeks, lips), or; with four or five characteristics of disfigurement

50
Description Percentage

With visible or palpable tissue loss and either gross distortion or asymmetry of one feature or paired set of features (nose, chin, forehead, eyes (including eyelids), ears (auricles), cheeks, lips), or; with two or three characteristics of disfigurement

30
Description Percentage

With one characteristic of disfigurement

10

Note (1): The 8 characteristics of disfigurement, for purposes of evaluation under §4.118, are:

Scar 5 or more inches (13 or more cm.) in length. Scar at least one-quarter inch (0.6 cm.) wide at widest part.

Surface contour of scar elevated or depressed on palpation.

Scar adherent to underlying tissue.

Skin hypo-or hyper-pigmented in an area exceeding six square inches (39 sq. cm.).

Skin texture abnormal (irregular, atrophic, shiny, scaly, etc.) in

an area exceeding six square inches (39 sq. cm.).

Underlying soft tissue missing in an area exceeding six square inches (39 sq. cm.).

Skin indurated and inflexible in an area exceeding six square inches (39 sq. cm.).

 

Note (2): Rate tissue loss of the auricle under DC 6207 (loss of auricle) and anatomical loss of the eye under DC 6061 (anatomical loss of both eyes) or DC 6063 (anatomical loss of one eye), as appropriate.

Note (3): Take into consideration unretouched color photographs when evaluating under these criteria.

Note (4): Separately evaluate disabling effects other than disfigurement that are associated with individual scar(s) of the head, face, or neck, such as pain, instability, and residuals of associated muscle or nerve injury, under the appropriate diagnostic code(s) and apply § 4.25 to combine the evaluation(s) with the evaluation assigned under this diagnostic code.

Note (5): The characteristic(s) of disfigurement may be caused by one scar or by multiple scars; the characteristic(s) required to assign a particular evaluation need not be caused by a single scar in order to assign that evaluation.

Description Percentage

With visible or palpable tissue loss and either gross distortion or asymmetry of three or more features or paired sets of features (nose, chin, forehead, eyes (including eyelids), ears (auricles), cheeks, lips), or; with six or more characteristics of disfigurement

80
Description Percentage

Area or areas of 144 square inches (929 sq. cm.) or greater

40
Description Percentage

Area or areas of at least 72 square inches (465 sq. cm.) but less than 144 square inches (929 sq. cm.)

30
Description Percentage

Area or areas of at least 12 square inches (77 sq. cm.) but less than 72 square inches (465 sq. cm.)

20
Description Percentage

Area or areas of at least 6 square inches (39 sq. cm.) but less than 12 square inches (77 sq. cm.)

10
Description Percentage

Five or more scars that are unstable or painful

30
Description Percentage

Three or four scars that are unstable or painful

20
Description Percentage

One or two scars that are unstable or painful

10

Note (1): An unstable scar is one where, for any reason, there is frequent loss of covering of skin over the scar.

 

Note (2): If one or more scars are both unstable and painful, add 10 percent to the evaluation that is based on the total number of unstable or painful scars.

 

Note (3): Scars evaluated under diagnostic codes 7800, 7801, , or 7800-7801--or-7804" target="_blank">7805 may also receive an evaluation under this diagnostic code, when applicable.


Note (1): An unstable scar is one where, for any reason, there is frequent loss of covering of skin over the scar.

 

Note (2): If one or more scars are both unstable and painful, add 10 percent to the evaluation that is based on the total number of unstable or painful scars.

 

Note (3): Scars evaluated under diagnostic codes 7800, 7801, , or 7800-7801--or-7804" target="_blank">7805 may also receive an evaluation under this diagnostic code, when applicable.

Evaluate under the General Rating Formula for the Skin

Evaluate under the General Rating Formula for the Skin

Description Percentage

With exposed areas affected

10
Description Percentage

With no exposed areas affected

0

Evaluate under the General Rating Formula for the Skin

Chronic urticaria:

What Are Hives?

Urticaria also commonly known as hives are red, bothersome welts that outcome from a skin reaction. The welts differ in estimate and show up and blur over and over as the reaction runs its course.

The condition is viewed as chronic urticaria if the welts show up for over about a month and a half and repeat oftentimes over months or years. Regularly, the reason for chronic hives isn't clear. Chronic hives can be entirely awkward and meddle with rest and every day exercises. For some individuals, antihistamines and hostile to tingle prescriptions give help.

Manifestations Of Chronic Hives

Signs and side effects of chronic hives include:

  • Bunches of red or skin-shaded welts (wheals), which can show up anyplace on the body
  • Welts that differ in size, change shape, and show up and blur over and over as the reaction runs its course
  • Itching, which might be serious
  • Excruciating swelling (angioedema) of the lips, eyelids and inside the throat
  • A propensity for signs and indications to erupt with triggers like warmth, exercise and stress
  • An inclination for signs and indications to continue for over about a month and a half and to repeat much of the time and unusually, once in a while for quite a long time or years
  • Present moment (intense) hives show up unexpectedly and clear up inside half a month.

When To See A Specialist

See your PCP in the event that you have extreme hives or hives that keep on showing up for a few days. You need to get immediate medical care in that case as it can cause more issues.

Chronic hives don't put you at any abrupt danger of a genuine unfavorably susceptible response (hypersensitivity). In the event that you do encounter hives as a feature of a genuine hypersensitivity, look for a suitable medical care provider. Signs and manifestations of hypersensitivity incorporate discombobulation, inconvenience breathing, and swelling of your lips, eyelids and tongue.

Description Percentage

Chronic refractory urticaria that requires third line treatment for control (e.g., plasmapheresis, immunotherapy, immunosuppressives) due to ineffectiveness with first and second line treatments

60
Description Percentage

Chronic urticaria that requires second line treatment (e.g., corticosteroids, sympathomimetics, leukotriene inhibitors, neutrophil inhibitors, thyroid hormone) for control

30
Description Percentage

Chronic urticaria that requires first line treatment (antihistamines) for control

10

Description Percentage

Persistent documented vasculitis episodes refractory to continuous immunosuppressive therapy

60
Description Percentage

All of the following

30
Description Percentage

Recurrent documented vasculitic episodes occurring four or more times over the past 12-month period; and Requiring intermittent systemic immunosuppressive therapy for control

30
Description Percentage

At least one of the following

10

Recurrent documented vasculitic episodes occurring one to three times over the past 12-month period, and requiring intermittent systemic immunosuppressive therapy for control; or Without recurrent documented vasculitic episodes but requiring continuous systemic medication for control. Or rate as disfigurement of the head, face, or neck (DC 7800) or scars (DCs 7801, 7802, 7804, or 7805), depending upon the predominant disability

Description Percentage

Recurrent mucosal, palmar, or plantar involvement impairing mastication, use of hands, or ambulation occurring four or more times over the past 12-month period despite ongoing immunosuppressive therapy

60
Description Percentage

All of the following

30

Description Percentage

At least one of the following

10

One to three episodes of mucosal, palmar, or plantar involvement not impairing mastication, use of hands, or ambulation, occurring over the past 12-month period AND requiring intermittent systemic therapy; or Without recurrent episodes, but requiring continuous systemic medication for control Or rate as disfigurement of the head, face, or neck (DC 7800) or scars (DCs 7801, , 7804, or 7805), depending upon the predominant disability

Note: For the purposes of this DC only, systemic therapy may consist of one or more of the following treatment agents: immunosuppressives, antihistamines, or sympathomimetics

Acne:

Acne

When hair follicles become stopped with oil, this typical skin condition is known as acne. It causes whiteheads, blackheads or pimples. Acne is generally normal among teens; however, it influences individuals, everything being equal. Successful acne medicines are accessible, yet acne can be persevering. The pimples and bumps recuperate gradually, and when one starts to disappear, others appear to manifest.

Contingent upon its severity, acne can cause enthusiastic pain and scar the skin. The previous you start treatment, the lower your danger of such issues.

Indications

Acne signs shift contingent upon the severity of your condition:

  • Whiteheads
  • Blackheads
  • Little red, delicate bumps (papules)
  • Pimples
  • Huge and strong, bumps under the skin
  • Cystic injuries

When To See A Specialist

In the event that self-care cures don't clear your acne, see your essential consideration specialist. The person can recommend more grounded meds. On the off chance that acne perseveres or is extreme, you might need to look for medical therapy from a specialist who spends significant time in the skin (dermatologist or pediatric dermatologist).

For some ladies, acne can endure for quite a long time, with flares regular seven days before menstruation. This kind of acne keeps an eye on clear up without treatment in ladies who use contraceptives. In more seasoned grown-ups, an abrupt beginning of serious acne may flag a hidden sickness requiring medical consideration.

Some administrations caution that some mainstream nonprescription acne moisturizers, cleaning agents and other skin items can cause a reaction on skin. This sort of reaction is very uncommon, so don't mistake it for any redness or irritation where you've applied meds or items. Go to your doctor immediately if you have the following symptoms:

  • Faintness
  • Trouble breathing
  • Swelling of the eyes, face, lips or tongue
  • Tightness of the throat

Description Percentage

Deep acne (deep inflamed nodules and pus-filled cysts) affecting 40 percent or more of the face and neck

30
Description Percentage

Deep acne (deep inflamed nodules and pus-filled cysts) affecting less than 40 percent of the face and neck, or deep acne other than on the face and neck

10
Description Percentage

Superficial acne (comedones, papules, pustules) of any extent Or rate as disfigurement of the head, face, or neck (DC 7800) or scars (DCs 7801, , 7804, or 7805), depending upon the predominant disability

0

Description Percentage

Deep acne (deep inflamed nodules and pus-filled cysts) affecting 40 percent or more of the face and neck

30
Description Percentage

Deep acne (deep inflamed nodules and pus-filled cysts) affecting the intertriginous areas (the axilla of the arm, the anogenital region, skin folds of the breasts, or between digits)

20
Description Percentage

Deep acne (deep inflamed nodules and pus-filled cysts) affecting less than 40 percent of the face and neck; or deep acne affecting non-intertriginous areas of the body (other than the face and neck)

10
Description Percentage

Superficial acne (comedones, papules, pustules) of any extent

0

Or rate as disfigurement of the head, face, or neck (DC 7800) or scars (DCs 7801, , 7804, or 7805), depending upon the predominant disability

Description Percentage

Affecting more than 40 percent of the scalp

20
Description Percentage

Affecting 20 to 40 percent of the scalp

10
Description Percentage

Affecting less than 20 percent of the scalp

0

Description Percentage

With loss of all body hair

10
Description Percentage

With loss of hair limited to scalp and face

0

Description Percentage

Unable to handle paper or tools because of moisture,  and unresponsive to therapy

30
Description Percentage

Able to handle paper or tools after therapy

0

Rate as scars (DC’s 7801, , , 7804, or 7800-7801-7802-or-7804" target="_blank">7805), disfigurement of the head, face, or neck (DC 7800), or impairment of function (under the  appropriate body system).

Note: If a skin malignancy requires therapy that is comparable to that used for systemic malignancies, i.e., systemic chemotherapy, X-ray therapy more extensive than to the skin, or surgery more extensive than wide local excision, a 100-percent evaluation will be assigned from the date of onset of treatment, and will continue, with a mandatory VA examination six months following the completion of such antineoplastic treatment, and any change in evaluation based upon that or any subsequent examination will be subject to the provisions of §3.105(e). If there has been no local recurrence or metastasis, evaluation will then be made on residuals. If treatment is confined to the skin, the provisions for a 100-percent evaluation do not apply. 

(a) For the purposes of this section, systemic therapy is treatment that is administered through any route (orally, injection, suppository, intranasally) other than the skin, and topical therapy is treatment that is administered through the skin.

 

(b) Two or more skin conditions may be combined in accordance with §4.25 only if separate areas of skin are involved. If two or more skin conditions involve the same area of skin, then only the highest evaluation shall be used.

Need help with Medical Compensation? If your disability claim is not clearly supported by your medical records along with evidence, your claim can be denied. We have helped thousands of Veterans claim the compensation they deserve.

Get More Info